Pfizer
is preparing to pull again on early-phase research into treatments for exceptional illnesses, which include the development of new viral-dependent gene therapies, the business advised staff members on Thursday afternoon.
The firm reported it would “externalize” most of its early-stage exceptional ailment courses in neurology and cardiology, and gene remedy applications not still in medical trials. Among the assets on the chopping block is gene treatment producing facility in Durham, North Carolina, in which the enterprise announced in December 2021 it was investing just about $70 million.
Pfizer
is preparing to pull again on early-phase research into treatments for exceptional illnesses, which include the development of new viral-dependent gene therapies, the business advised staff members on Thursday afternoon.
The firm reported it would “externalize” most of its early-stage exceptional ailment courses in neurology and cardiology, and gene remedy applications not still in medical trials. Among the assets on the chopping block is gene treatment producing facility in Durham, North Carolina, in which the enterprise announced in December 2021 it was investing just about $70 million.
